Bio-Techne Corp TECH has seen significant fluctuations in recent times, with a wave of investor concerns causing a drop in the company's share prices. There were worries the company's value increased prematurely. However, amidst these challenges, strong trading days have seen them outperform their competitors. Citi upgraded Bio-Techne to 'Buy' from 'Neutral', setting a new price target at $70. Bio-Techne also reported strong organic growth globally while declaring a dividend. Bio-Techne went through a divestiture of its Exosome Diagnostics division, intending to expand its margin by 100 basis points for FY26. Bio-Techne's earnings have been mostly positive, beating estimates, largely due to strong revenue growth. Furthermore, the company announced strategic collaborations that are expected to expatiate gene therapy product development. There are, however, concerns about NIH funding and research spending, which have led to further fluctuations in the stock. Lastly, a newly announced $500M share repurchase program presumably plays a part in its future financial strategies.
Bio-Techne Corp TECH News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Fri, 22 Aug 2025 22:23:23 GMT -
Rating 6
- Innovation 5
- Information 8
- Rumor -2
